FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965578843> ?p ?o ?g. }

• W2965578843 abstract "To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their cardiovascular, renal, and safety outcomes. The composite renal outcome event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 3.7, 7.0, 47%; 5.5, 9.0, 40%; 6.3, 11.5, 46%; 43.2, 61.2, 30% for DECLARE-TIMI 58, CANVAS, EMPA–REG OUTCOME, and CREDENCE, respectively (event definitions varied across trials). The major adverse cardiovascular (CV) event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 22.6, 24.2, 7%; 26.9, 31.5, 14%; 37.4, 43.9, 14%; 38.7, 48.7, 20% for DECLARE-TIMI 58, CANVAS, EMPA–REG OUTCOME, and CREDENCE, respectively. DECLARE-TIMI 58 had the fewest cardiorenal events and CREDENCE the most. These differences were presumably due to varying inclusion criteria resulting in DECLARE-TIMI 58 having the best baseline renal filtration function and CREDENCE the worst (mean estimated glomerular filtration rate 85.2, 76.5, 74, 56.2 mL/min/1.73 m2 for DECLARE-TIMI 58, CANVAS, EMPA–REG OUTCOME, and CREDENCE, respectively). Additionally, CREDENCE had considerably higher rates of albuminuria (median urinary albumin-creatinine ratios (UACR) were 927, 12.3, and 13.1 mg/g for CREDENCE, CANVAS, and DECLARE-TIMI 58, respectively; EMPA–REG OUTCOME had 59.4% UACR < 30, 28.6% UACR > 30–300, 11.0% UACR > 300 mg/g). Dapagliflozin, empagliflozin, and canagliflozin have internally and externally consistent and biologically plausible class effects on cardiorenal outcomes. Baseline renal filtration function and degree of albuminuria are the most significant indicators of risk for both CV and renal events. Thus, these two factors also anticipate the greatest clinical benefit for SGLT2i." @default.
• W2965578843 created "2019-08-13" @default.
• W2965578843 creator A5001846180 @default.
• W2965578843 creator A5008382551 @default.
• W2965578843 creator A5023736069 @default.
• W2965578843 creator A5025868173 @default.
• W2965578843 creator A5027816601 @default.
• W2965578843 creator A5043161884 @default.
• W2965578843 creator A5047867576 @default.
• W2965578843 creator A5091076246 @default.
• W2965578843 date "2019-08-05" @default.
• W2965578843 modified "2023-10-17" @default.
• W2965578843 title "Class effects of SGLT2 inhibitors on cardiorenal outcomes" @default.
• W2965578843 cites W1484562653 @default.
• W2965578843 cites W1491124385 @default.
• W2965578843 cites W1570583414 @default.
• W2965578843 cites W1986373594 @default.
• W2965578843 cites W1990724339 @default.
• W2965578843 cites W2004545653 @default.
• W2965578843 cites W2012282857 @default.
• W2965578843 cites W2013453412 @default.
• W2965578843 cites W2016188383 @default.
• W2965578843 cites W2047507222 @default.
• W2965578843 cites W2072550407 @default.
• W2965578843 cites W2112704642 @default.
• W2965578843 cites W2114250030 @default.
• W2965578843 cites W2131490500 @default.
• W2965578843 cites W2137625135 @default.
• W2965578843 cites W2137784332 @default.
• W2965578843 cites W2146264128 @default.
• W2965578843 cites W2155965977 @default.
• W2965578843 cites W2164249826 @default.
• W2965578843 cites W2196574894 @default.
• W2965578843 cites W2338303859 @default.
• W2965578843 cites W2424539745 @default.
• W2965578843 cites W2464585615 @default.
• W2965578843 cites W2511256663 @default.
• W2965578843 cites W2612486405 @default.
• W2965578843 cites W2626354203 @default.
• W2965578843 cites W2626446274 @default.
• W2965578843 cites W2755083612 @default.
• W2965578843 cites W2782992901 @default.
• W2965578843 cites W2790193266 @default.
• W2965578843 cites W2793906475 @default.
• W2965578843 cites W2797818831 @default.
• W2965578843 cites W2801716806 @default.
• W2965578843 cites W2804137450 @default.
• W2965578843 cites W2806818105 @default.
• W2965578843 cites W2806864111 @default.
• W2965578843 cites W2808725516 @default.
• W2965578843 cites W2808939545 @default.
• W2965578843 cites W2883091608 @default.
• W2965578843 cites W2884101530 @default.
• W2965578843 cites W2887280388 @default.
• W2965578843 cites W2887650349 @default.
• W2965578843 cites W2894852767 @default.
• W2965578843 cites W2899764361 @default.
• W2965578843 cites W2900413769 @default.
• W2965578843 cites W2902527999 @default.
• W2965578843 cites W2908065012 @default.
• W2965578843 cites W2927116591 @default.
• W2965578843 cites W2936559636 @default.
• W2965578843 cites W2939222610 @default.
• W2965578843 cites W2944717765 @default.
• W2965578843 doi "https://doi.org/10.1186/s12933-019-0903-4" @default.
• W2965578843 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6683461" @default.
• W2965578843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31382965" @default.
• W2965578843 hasPublicationYear "2019" @default.
• W2965578843 type Work @default.
• W2965578843 sameAs 2965578843 @default.
• W2965578843 citedByCount "108" @default.
• W2965578843 countsByYear W29655788432018 @default.
• W2965578843 countsByYear W29655788432019 @default.
• W2965578843 countsByYear W29655788432020 @default.
• W2965578843 countsByYear W29655788432021 @default.
• W2965578843 countsByYear W29655788432022 @default.
• W2965578843 countsByYear W29655788432023 @default.
• W2965578843 crossrefType "journal-article" @default.
• W2965578843 hasAuthorship W2965578843A5001846180 @default.
• W2965578843 hasAuthorship W2965578843A5008382551 @default.
• W2965578843 hasAuthorship W2965578843A5023736069 @default.
• W2965578843 hasAuthorship W2965578843A5025868173 @default.
• W2965578843 hasAuthorship W2965578843A5027816601 @default.
• W2965578843 hasAuthorship W2965578843A5043161884 @default.
• W2965578843 hasAuthorship W2965578843A5047867576 @default.
• W2965578843 hasAuthorship W2965578843A5091076246 @default.
• W2965578843 hasBestOaLocation W29655788431 @default.
• W2965578843 hasConcept C126322002 @default.
• W2965578843 hasConcept C134018914 @default.
• W2965578843 hasConcept C159641895 @default.
• W2965578843 hasConcept C164705383 @default.
• W2965578843 hasConcept C2775887513 @default.
• W2965578843 hasConcept C2776442814 @default.
• W2965578843 hasConcept C2777180221 @default.
• W2965578843 hasConcept C2777422806 @default.
• W2965578843 hasConcept C2777451236 @default.
• W2965578843 hasConcept C2777995511 @default.
• W2965578843 hasConcept C2780400711 @default.
• W2965578843 hasConcept C2781308992 @default.
• W2965578843 hasConcept C500558357 @default.

• next